Healthcare built for real life requires a complete reinvention of the current experience. Not an add-on feature or a retrofit. Starting today, we’re launching a fundamental reimagining of what it means to get people closer to feeling great. @wearehers weight loss members are the first ones to feel it today, and we’re planning to bring it to all of our members soon. Watch this space. We’re just getting started.

Love this @buzzfeed conversation with @dankenger. Brilliant design has the ability to power deeper connections with our customers, so it’s at the center of everything we do. An experience that people can trust and actually enjoy transforms health. Our in-house creative team is showing the world what’s possible when you bring that to millions. 🚀✨ buzzfeed.com/business-news/h…

We founded Hims & Hers to help more people feel great. To disrupt a broken healthcare system and create a new model of health where innovators work together to deliver access to care that actually serves everyday people. We align how we operate with where we see major growth opportunities and in a way that allows us to meet our customers where they are (and where they want to go). That’s why, later this month, Hims & Hers customers will have access to FDA-approved medications from @novonordisk as a part of a strategic collaboration. The weight loss landscape is completely different today than it was when we first entered the category. FDA-approved GLP-1 treatments are now more accessible, with greater affordability and more flexible dosing options and form factors. These market changes are shifting consumer demand towards these branded medications. We’re moving our model forward another step with this strategic shift in our US weight loss business. This evolution will make us the largest global consumer health platform providing access to more affordable, approved medications. We will continue to innovate across our platform, keeping what’s best for consumers as our North Star. There's challenging, important work in front of us, and I've never been more excited about the path ahead. Just like we always do, Hims & Hers will rise to meet the moment. More here: investors.hims.com/news/news… Important info here: news.hims.com/disclaimers/di…

Tonight, when our ad airs during the Big Game, we will continue a much-needed conversation around what healthcare should look and feel like in America: affordable, proactive, personalized. When we start hard conversations, we expect challenges along the way. But we won't ever stop advocating for better until the system becomes better for everyone. news.hims.com/newsroom/the-h…

To our customers (both future and current): I have always believed that in order to change something, you have to be willing to have a tough conversation. We’ve done that as a company since we launched in 2017 because we know progress requires honesty before it provides hope. Our latest ad, which will air at the big game next weekend, is meant to provoke a long overdue tough conversation. It’s meant to recognize that you deserve better. No one should be satisfied with a system that requires you to get sick before you’re allowed to get healthy. This isn’t about advertising any one specific treatment. This is about speaking directly to you about the future we know all Americans deserve, whether you live in a rural community, a big city, or somewhere in between. This is about being a loud, unapologetic advocate for what we know care can and should look like for everyone in this country: affordable, proactive, and built to empower the individual. In order for health outcomes in the US to really improve, we have to stop gatekeeping innovative, proactive tools and care. Real, lasting health requires having access to transparent information *and* innovation that can help prevent - not just treat - disease. Meaningful change requires two things: the conviction to reimagine a better way and the stamina to make it a reality. My promise to all of you is that I’ll make sure Hims & Hers always has both. Let’s close the health gap.

This morning we launched Labs, the easiest and most comprehensive way to get a real understanding of your health. Labs offers an annual subscription that tests up to 120 of the most critical biomarkers in your body, for just a few hundred dollars. From genetic cardiovascular numbers to metabolic syndrome, these are the biomarkers at the cutting edge of innovation. Data is helpful, but what comes next is what matters. Immediately when your results are in, our platform in partnership with thousands of doctors, nurses and providers will provide you with a specific analysis and action plan. Nutrition, movement, supplements, and personalized medication options. With over 1M square feet of pharmacy infrastructure, Hims & Hers doesn’t just test your health metrics, but unlocks your ability to actually improve them with access to precision treatments and care. This is the first offering with Hims & Hers I’m encouraging all of my family and friends to sign up for. The power of knowledge and early action is unmatched, and for the people we love there is no greater gift. news.hims.com/newsroom/intro…

We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk’s commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company’s anticompetitive demands that infringe on the independent decision making of providers and limit patient choice. We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first. We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients.

We just shared our Q1 results. And our 2030 target: $6.5B in revenue, $1.3B in adjusted EBITDA. We're entering a new era of growth: deeper personalization, broader impact, and faster execution. The foundation is set. The roadmap is clear. We're just getting started.